The issue that could tear Trump's base apart Capitol Hill was blanketed in protesters earlier this week as lawmakers debated ...

Biotech, one of the Bay Area's most important industries, sprang up in five short decades. Here are the key moments to know ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Gilead Sciences’ long-acting drug to block HIV has the potential to end the AIDS epidemic worldwide. But accessibility ...

South Africa made massive progress in reducing transmission of HIV from mothers to their babies. Even so, about 7,000 babies still contract the virus every year. Experts put this down to having the ...

There are several ways to address HIV in homeless populations, with the most promising being the low barrier care model, ...

South Africa made massive progress in reducing transmission of HIV from mothers to their babies. Even so, about 7 000 babies still contract the virus every year. Experts put this down to having the ...

Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral ...

Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host ...

Leading data and analytics company GlobalData’s report, Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast, ...

It is possible to coach the immune system to generate super power antibodies that can block HIV from attacking your cells.

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.